Amarin Corporation

Amarin Corporation Enterprise Value

The Enterprise Value (EV) of Amarin Corporation (AMRN) as of Nov 19, 2026 is 20.28 M USD. In the previous year, Enterprise Value (EV) was 24.41 M USD — a change of -16.93% (lower).

Enterprise Value

20.28 MUSD

YoY

-16.93%

Last updated:

Enterprise Value (EV) of Amarin Corporation is 2025 20.28 M USD. Enterprise Value (EV) of Amarin Corporation was 2024 24.41 M USD. It decreases by -16.93% lower compared to the previous year.

The Amarin Corporation Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
142.03 M USD
Jan 1, 2019
-274.10 M USD
Jan 1, 2020
-180.87 M USD
Jan 1, 2021
-134.64 M USD
Jan 1, 2022
11.57 M USD
Jan 1, 2023
-1.01 M USD
Jan 1, 2024
24.41 M USD
Jan 1, 2025
20.28 M USD
The Amarin Corporation Enterprise Value history
YEAREnterprise ValueYoY
20.28 MUSD-16.93%
24.41 MUSD-2,517.15%
-1.01 MUSD-108.73%
11.57 MUSD-108.59%
-134.64 MUSD-25.56%
-180.87 MUSD-34.01%
-274.10 MUSD-292.99%
142.03 MUSD-60.54%
359.93 MUSD+9.36%
329.11 MUSD-27.69%
455.11 MUSD+8.82%
418.23 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amarin Corporation stock

Enterprise Value (EV) of Amarin Corporation is 20.28 M USD in 2025.

Enterprise Value (EV) of Amarin Corporation changed from 24.41 M USD to 20.28 M USD, representing a -16.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Amarin Corporation with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Amarin Corporation

All Key Metrics — Amarin Corporation